Amendments to the Specification:

Please replace the paragraph at page 1, lines 7-10 with the following amended paragraph:

Cross-Reference to Related Application

This application is a continuation-in-part of copending U.S. Application Serial No. 10/309,527, filed December 3, 2002, now U.S. Pat. 7,022,700, the entire disclosure of which is incorporated herein by reference.

Please replace the paragraph beginning at page 27, line 1 with the following amended paragraph.

For treating or preventing neutropenia, the specific dose of compound according to the invention to obtain therapeutic benefit will, of course, be determined by the particular circumstances of the individual patient including, the size, weight, age and sex of the patient. Also determinative will be the nature and stage of the disease and the route of administration. For example, a daily dosage of from about 100 to 1500 mg[[/kg]]/day may be utilized. Preferably, a daily dosage of from about 100 to 1000 mg[[/kg]]/day may be utilized. More preferably, a daily dosage of from about 100 to 500 mg[[/kg]]/day may be utilized. Higher or lower doses are also contemplated. Neutrophil levels may be monitored in the patient and the treatment regimen may be maintained until neutrophil levels reach a normal range.